Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00028795
Status:
COMPLETED
Last Update Posted:
2014-02-21
First Post:
2002-01-04
Brief Title:
Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma Glioblastoma Multiforme Gliosarcoma or Diffuse Intrinsic Pontine Glioma
Sponsor:
Childrens Oncology Group
Organization:
Childrens Oncology Group
Study Overview
Official Title:
A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Radiation therapy uses high-energy x-rays to damage tumor cells Giving chemotherapy together with radiation therapy may kill more tumor cells
PURPOSE This phase II trial is studying how well giving chemotherapy together with radiation therapy after surgery followed by chemotherapy alone works in children with newly diagnosed astrocytoma glioblastoma multiforme gliosarcoma or diffuse intrinsic pontine glioma
PURPOSE This phase II trial is studying how well giving chemotherapy together with radiation therapy after surgery followed by chemotherapy alone works in children with newly diagnosed astrocytoma glioblastoma multiforme gliosarcoma or diffuse intrinsic pontine glioma
Detailed Description:
OBJECTIVES
Compare the event-free survival of patients with newly diagnosed anaplastic astrocytoma glioblastoma multiforme gliosarcoma or diffuse intrinsic pontine glioma DIPG treated with adjuvant temozolomide administered concurrently with postoperative radiotherapy and then alone as maintenance therapy vs historical control cohorts treated in prior Pediatric Oncology Group and Childrens Cancer Group studies
Determine the toxicity of this regimen in these patients
Determine the efficacy of this regimen in patients with DIPG
Determine the toxicity of this regimen in patients with DIPG
OUTLINE This is a multicenter study
Adjuvant chemoradiotherapy Beginning within 6 weeks after surgical resection or diagnosis patients without gross residual disease undergo cranial irradiation 5 days a week for 6 weeks Beginning within 6 weeks after surgical resection patients with gross residual disease undergo radiotherapy as above followed by boost radiotherapy for 1 week All patients receive oral temozolomide once daily beginning within 5 days after initiation of radiotherapy and continuing for a total of 6 weeks in the absence of disease progression or unacceptable toxicity
Adjuvant maintenance therapy Beginning 4 weeks after completion of adjuvant chemoradiotherapy patients receive oral temozolomide on days 1-5 Treatment repeats every 28 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity
NOTE For patients with diffuse intrinsic pontine glioma only
Patients are followed every 3-6 months for 4 years and then annually thereafter
PROJECTED ACCRUAL A total of 50-60 patients will be accrued for this study within 12-14 months
Compare the event-free survival of patients with newly diagnosed anaplastic astrocytoma glioblastoma multiforme gliosarcoma or diffuse intrinsic pontine glioma DIPG treated with adjuvant temozolomide administered concurrently with postoperative radiotherapy and then alone as maintenance therapy vs historical control cohorts treated in prior Pediatric Oncology Group and Childrens Cancer Group studies
Determine the toxicity of this regimen in these patients
Determine the efficacy of this regimen in patients with DIPG
Determine the toxicity of this regimen in patients with DIPG
OUTLINE This is a multicenter study
Adjuvant chemoradiotherapy Beginning within 6 weeks after surgical resection or diagnosis patients without gross residual disease undergo cranial irradiation 5 days a week for 6 weeks Beginning within 6 weeks after surgical resection patients with gross residual disease undergo radiotherapy as above followed by boost radiotherapy for 1 week All patients receive oral temozolomide once daily beginning within 5 days after initiation of radiotherapy and continuing for a total of 6 weeks in the absence of disease progression or unacceptable toxicity
Adjuvant maintenance therapy Beginning 4 weeks after completion of adjuvant chemoradiotherapy patients receive oral temozolomide on days 1-5 Treatment repeats every 28 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity
NOTE For patients with diffuse intrinsic pontine glioma only
Patients are followed every 3-6 months for 4 years and then annually thereafter
PROJECTED ACCRUAL A total of 50-60 patients will be accrued for this study within 12-14 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000069135 | OTHER | Clinical Trialsgov | None |
| COG-ACNS0126 | OTHER | None | None |